Endoscopic Therapy in Barrett Esophagus and Early Cancer

Video

This video reviews the use of endoscopic therapy for the management of Barrett esophagus and early esophageal cancer.

In this video, Prateek Sharma, MD, of the University of Kansas Medical Center, discusses highlights from his presentation on endoscopic therapy for the management of Barrett esophagus and early esophageal cancer.

Sharma spoke on this topic at an extended education session, “Management of Complex Upper Gastrointestinal Cases: Implementation of Best Evidence,” at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, on June 2 in Chicago.

Related Videos
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.
Patients with unresectable or metastatic esophageal squamous cell carcinoma and higher PD-L1 expression may benefit from treatment with tislelizumab, according to Syma Iqbal, MD.
Quantifying disease volume to help identify potential recurrence following surgery may be a helpful advance, according to Sean Dineen, MD.
Tanios S. Bekaii-Saab, MD, and the Oncology Brothers presenting slides
Tanios S. Bekaii-Saab, MD, and the Oncology Brothers presenting slides
Tanios S. Bekaii-Saab, MD, and the Oncology Brothers presenting slides
Tanios S. Bekaii-Saab, MD, and the Oncology Brothers presenting slides
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.